By conjugating the covalent nanobody to a cell penetrating peptide consisting of a nona-d-arginine peptide and a lysosomal-sorting sequence (NPGY), the resultant GlueTAC led to the internalization and lysosomal degradation of more than 89% of PD-L1 and showed sustained T-cell activation and tumor growth inhibition. This evidence concerns the gene CD274 and neoplasm.